Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
SUMO2 pseudogene 16 is a non-functional pseudogene originating from the Small Ubiquitin-like Modifier 2 (SUMO2) gene. It does not encode a functional protein, enzyme, receptor, or transporter, and is not considered a therapeutic target. Pseudogenes like SUMO2P16 are typically the result of ancient gene duplication or retrotransposition events and do not have biological activity. The parent gene, SUMO2, participates in the post-translational modification of proteins, playing critical roles in nuclear transport, transcriptional regulation, apoptosis, and protein stability[1][4]. In contrast, SUMO2 pseudogene 16 (and other SUMO2 pseudogenes) do not contribute to these functions, nor are they involved in human disease or drug interactions. If you need details about the functional SUMO2 gene (not the pseudogene), further information is available, including its role in protein modification, cell cycle, and disease associations[1][2][4][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on SUMO2 pseudogene 16 (SUMO2P16).